AspiAir GmbH is developing inhaled treatments with acetylsalicylic acid in different indications. The Company’s lead formulation is an inhaled LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®). It is suitable as an ingredient for an inhalable aerosol and has been successfully investigated in several clinical studies.
AspiAir was founded in 2019 and acquired all assets from Ventaleon GmbH, that developed inhaled LASAG for the indication of severe influenza up to Phase 2.
AspiAir is a portfolio company of ATON GmbH, Munich.